ADAM9 and hepatocellular carcinoma: Similarly, regorafenib, another multi-kinase inhibitor, lowered ADAM9 and additionally ADAM10 levels in sorafenib-resistant HCC cases, contributing to the accumulation of MICA on HCC cell membranes and the dual inhibitory effect partially explaining its clinical advantage over sorafenib [127].